AU2016235147B2 - Antimicrobial peptides and methods of use thereof - Google Patents
Antimicrobial peptides and methods of use thereof Download PDFInfo
- Publication number
- AU2016235147B2 AU2016235147B2 AU2016235147A AU2016235147A AU2016235147B2 AU 2016235147 B2 AU2016235147 B2 AU 2016235147B2 AU 2016235147 A AU2016235147 A AU 2016235147A AU 2016235147 A AU2016235147 A AU 2016235147A AU 2016235147 B2 AU2016235147 B2 AU 2016235147B2
- Authority
- AU
- Australia
- Prior art keywords
- antimicrobial
- amino acid
- composition
- seq
- amphipathic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108700042778 Antimicrobial Peptides Proteins 0.000 title claims description 70
- 102000044503 Antimicrobial Peptides Human genes 0.000 title claims description 70
- 238000000034 method Methods 0.000 title description 19
- 230000000845 anti-microbial effect Effects 0.000 claims description 72
- 239000000203 mixture Substances 0.000 claims description 56
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 36
- 230000002209 hydrophobic effect Effects 0.000 claims description 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 31
- 150000001413 amino acids Chemical class 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 239000004599 antimicrobial Substances 0.000 claims description 16
- 230000001580 bacterial effect Effects 0.000 claims description 16
- 230000002147 killing effect Effects 0.000 claims description 12
- 125000002091 cationic group Chemical group 0.000 claims description 10
- 239000000539 dimer Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- 239000012867 bioactive agent Substances 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 108010087765 Antipain Proteins 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
- 230000001062 anti-nausea Effects 0.000 claims description 2
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 claims description 2
- 239000002702 enteric coating Substances 0.000 claims description 2
- 238000009505 enteric coating Methods 0.000 claims description 2
- 244000000010 microbial pathogen Species 0.000 claims description 2
- 229940124583 pain medication Drugs 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 110
- 102000004196 processed proteins & peptides Human genes 0.000 description 76
- 229920001184 polypeptide Polymers 0.000 description 53
- 125000000539 amino acid group Chemical group 0.000 description 51
- 235000001014 amino acid Nutrition 0.000 description 38
- 241000894006 Bacteria Species 0.000 description 29
- 229940024606 amino acid Drugs 0.000 description 28
- 230000000813 microbial effect Effects 0.000 description 19
- 125000005647 linker group Chemical group 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 230000003115 biocidal effect Effects 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 5
- 241000193163 Clostridioides difficile Species 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 229920000037 Polyproline Polymers 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000588626 Acinetobacter baumannii Species 0.000 description 4
- 241000588914 Enterobacter Species 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000000843 anti-fungal effect Effects 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 125000001165 hydrophobic group Chemical group 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 3
- 241000581608 Burkholderia thailandensis Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 241000605986 Fusobacterium nucleatum Species 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 206010029803 Nosocomial infection Diseases 0.000 description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229960000484 ceftazidime Drugs 0.000 description 3
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229960003104 ornithine Drugs 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000589513 Burkholderia cepacia Species 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 241000222178 Candida tropicalis Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000194031 Enterococcus faecium Species 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- 241000235645 Pichia kudriavzevii Species 0.000 description 2
- 241000605862 Porphyromonas gingivalis Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 206010041925 Staphylococcal infections Diseases 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000000842 anti-protozoal effect Effects 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000003555 cloaca Anatomy 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 230000005661 hydrophobic surface Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000001974 tryptic soy broth Substances 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 description 1
- MHJJUOJOAJLYBS-ZBRNBAAYSA-N (2s)-2-aminopropanoic acid;(2s)-pyrrolidine-2-carboxylic acid Chemical compound C[C@H](N)C(O)=O.OC(=O)[C@@H]1CCCN1 MHJJUOJOAJLYBS-ZBRNBAAYSA-N 0.000 description 1
- YWOLSBHQLNEVOL-DNVVRKGNSA-N (2s,3s)-2-amino-3-methylpentanoic acid;(2s)-2-aminopentanedioic acid Chemical compound CC[C@H](C)[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O YWOLSBHQLNEVOL-DNVVRKGNSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- NOLKGSFXJRBRHD-GDOBSTBCSA-N C(=O)N[C@@H](CCSC)C(=O)O.N[C@@H](C[SeH])C(=O)O.NCC(=O)O Chemical compound C(=O)N[C@@H](CCSC)C(=O)O.N[C@@H](C[SeH])C(=O)O.NCC(=O)O NOLKGSFXJRBRHD-GDOBSTBCSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 150000008574 D-amino acids Chemical group 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000283070 Equus zebra Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 241000282816 Giraffa camelopardalis Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- -1 HAS Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical group 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- ZFOMKMMPBOQKMC-KXUCPTDWSA-N L-pyrrolysine Chemical compound C[C@@H]1CC=N[C@H]1C(=O)NCCCC[C@H]([NH3+])C([O-])=O ZFOMKMMPBOQKMC-KXUCPTDWSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000282374 Puma concolor Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000282458 Ursus sp. Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001576 beta-amino acids Chemical group 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000004040 defense response to microbe Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019222918A AU2019222918B2 (en) | 2015-03-23 | 2019-08-30 | Antimicrobial peptides and methods of use thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562137206P | 2015-03-23 | 2015-03-23 | |
| US62/137,206 | 2015-03-23 | ||
| PCT/US2016/023801 WO2016154328A2 (en) | 2015-03-23 | 2016-03-23 | Antimicrobial peptides and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019222918A Division AU2019222918B2 (en) | 2015-03-23 | 2019-08-30 | Antimicrobial peptides and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016235147A1 AU2016235147A1 (en) | 2017-10-26 |
| AU2016235147B2 true AU2016235147B2 (en) | 2019-09-19 |
Family
ID=56978879
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016235147A Ceased AU2016235147B2 (en) | 2015-03-23 | 2016-03-23 | Antimicrobial peptides and methods of use thereof |
| AU2019222918A Ceased AU2019222918B2 (en) | 2015-03-23 | 2019-08-30 | Antimicrobial peptides and methods of use thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019222918A Ceased AU2019222918B2 (en) | 2015-03-23 | 2019-08-30 | Antimicrobial peptides and methods of use thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10017542B2 (enExample) |
| EP (2) | EP3903823A3 (enExample) |
| JP (2) | JP6964577B2 (enExample) |
| KR (1) | KR20180002618A (enExample) |
| CN (2) | CN107614004B (enExample) |
| AU (2) | AU2016235147B2 (enExample) |
| CA (1) | CA2981705A1 (enExample) |
| WO (1) | WO2016154328A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2981705A1 (en) * | 2015-03-23 | 2016-09-29 | Riptide Bioscience, Inc. | Antimicrobial peptides and methods of use thereof |
| GB201812972D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| GB201812980D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| US10413584B1 (en) | 2018-08-29 | 2019-09-17 | Riptide Bioscience, Inc. | Peptides having immunomodulatory properties |
| KR20210052473A (ko) * | 2018-08-29 | 2021-05-10 | 립타이드 바이오사이언스, 인코포레이티드 | 면역조정 특성을 갖는 펩티드 |
| US20200102356A1 (en) * | 2018-10-01 | 2020-04-02 | NMC Inc. | Compositions and Methods for the Treatment of Huanglongbing (HLB) aka Citrus Greening in Citrus Plants |
| US10548944B1 (en) * | 2018-10-19 | 2020-02-04 | Riptide Bioscience, Inc. | Antimicrobial peptides and methods of using the same |
| CA3116537A1 (en) * | 2018-10-19 | 2020-04-23 | Riptide Bioscience, Inc. | Antimicrobial peptides and methods of using the same |
| BR112021010982A2 (pt) | 2018-12-07 | 2021-08-31 | Oxford University Innovation Limited | Ligantes |
| JP7390741B2 (ja) * | 2019-04-04 | 2023-12-04 | 國立臺灣▲海▼洋大學 | カーボン量子ドット、カーボン量子ドットの製造方法及び抗菌組成物。 |
| CN110305193B (zh) * | 2019-07-18 | 2021-10-08 | 河南科技大学 | 一种抗牙龈卟啉单胞菌多肽及应用 |
| CN116134045A (zh) * | 2021-09-03 | 2023-05-16 | 深圳千越生物科技有限公司 | 抗菌肽或肽衍生物、替换体以及其组合物、制备方法和应用 |
| CN114989254B (zh) * | 2022-06-17 | 2023-11-03 | 中山大学 | 一种多肽及其设计方法和在制备抑制具核梭杆菌产品或预防结直肠癌药物中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7803755B2 (en) * | 2006-12-21 | 2010-09-28 | Jesse Jaynes | Molecules for the treatment and prevention of fungal diseases |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI905825A0 (fi) * | 1988-05-27 | 1990-11-26 | Magainin Sciences Inc | Amfifiliska peptider och deras anvaendning. |
| ATE189231T1 (de) * | 1989-04-10 | 2000-02-15 | Helix Biomedix Inc | Lytische peptide, verwendung als wachstumsfördernde mittel und für infektionen und krebs |
| US5561107A (en) * | 1993-06-04 | 1996-10-01 | Demeter Biotechnologies, Ltd. | Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides |
| IL114697A0 (en) * | 1994-07-22 | 1995-11-27 | Demeter Biotech Ltd | Polypeptides comprising ubiquitin-lytic peptide fusion protein products deriving therefrom their preparation and use |
| JPH08134075A (ja) * | 1994-11-02 | 1996-05-28 | Yamanouchi Pharmaceut Co Ltd | 新規なカルバペネム誘導体 |
| WO1997029765A1 (en) * | 1996-02-16 | 1997-08-21 | The Regents Of The University Of California | Antimicrobial peptides and methods of use |
| WO1998014201A1 (en) * | 1996-10-04 | 1998-04-09 | Demegen, Inc. | Method for treatment of immunodeficiency virus infection |
| US6680058B1 (en) * | 1997-09-03 | 2004-01-20 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for contraception in or sterilization of mammals |
| IL146743A0 (en) * | 1999-05-31 | 2002-07-25 | Novozymes As | Screening method for peptides |
| US6432415B1 (en) * | 1999-12-17 | 2002-08-13 | Axrix Laboratories, Inc. | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
| WO2004033715A1 (en) * | 2002-10-09 | 2004-04-22 | Novozymes A/S | A method for screening for an antimicrobial polypeptide |
| EP2357190A3 (en) * | 2005-12-22 | 2011-08-24 | Novabiotics Limited | Cyclic antimicrobial peptides |
| EP2004674B1 (en) * | 2006-03-23 | 2013-02-20 | Agriculture Victoria Services Pty Ltd | Antimicrobial protein |
| ES2476590T3 (es) * | 2006-05-16 | 2014-07-15 | Pergamum Ab | P�ptidos antimicrobianos mejorados |
| US7288622B1 (en) * | 2006-09-19 | 2007-10-30 | Issar Pharmaceuticals Pvt Ltd | Composition for treatment of burns and wounds |
| US9163066B2 (en) * | 2010-06-29 | 2015-10-20 | Agromed Llc | Antimicrobial lytic peptides |
| EP2468856A1 (en) * | 2010-12-23 | 2012-06-27 | Lysando Aktiengesellschaft | Antimicrobial Agents |
| CA2981705A1 (en) * | 2015-03-23 | 2016-09-29 | Riptide Bioscience, Inc. | Antimicrobial peptides and methods of use thereof |
-
2016
- 2016-03-23 CA CA2981705A patent/CA2981705A1/en not_active Abandoned
- 2016-03-23 CN CN201680025771.3A patent/CN107614004B/zh active Active
- 2016-03-23 KR KR1020177030183A patent/KR20180002618A/ko not_active Withdrawn
- 2016-03-23 EP EP20197578.6A patent/EP3903823A3/en not_active Withdrawn
- 2016-03-23 EP EP16769619.4A patent/EP3274472B1/en active Active
- 2016-03-23 JP JP2018502035A patent/JP6964577B2/ja active Active
- 2016-03-23 US US15/078,794 patent/US10017542B2/en active Active
- 2016-03-23 AU AU2016235147A patent/AU2016235147B2/en not_active Ceased
- 2016-03-23 CN CN202211040273.XA patent/CN115475232A/zh active Pending
- 2016-03-23 WO PCT/US2016/023801 patent/WO2016154328A2/en not_active Ceased
-
2018
- 2018-06-05 US US16/000,709 patent/US20190071470A1/en not_active Abandoned
-
2019
- 2019-08-30 AU AU2019222918A patent/AU2019222918B2/en not_active Ceased
-
2020
- 2020-12-15 JP JP2020207711A patent/JP7267251B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7803755B2 (en) * | 2006-12-21 | 2010-09-28 | Jesse Jaynes | Molecules for the treatment and prevention of fungal diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107614004B (zh) | 2022-12-06 |
| AU2016235147A1 (en) | 2017-10-26 |
| US20160296594A1 (en) | 2016-10-13 |
| JP6964577B2 (ja) | 2021-11-10 |
| JP7267251B2 (ja) | 2023-05-01 |
| EP3903823A3 (en) | 2022-02-23 |
| EP3274472B1 (en) | 2020-09-23 |
| EP3274472A4 (en) | 2018-12-05 |
| US10017542B2 (en) | 2018-07-10 |
| KR20180002618A (ko) | 2018-01-08 |
| JP2018512454A (ja) | 2018-05-17 |
| AU2019222918B2 (en) | 2021-10-21 |
| US20190071470A1 (en) | 2019-03-07 |
| EP3274472A2 (en) | 2018-01-31 |
| EP3903823A2 (en) | 2021-11-03 |
| CN115475232A (zh) | 2022-12-16 |
| JP2021054842A (ja) | 2021-04-08 |
| WO2016154328A2 (en) | 2016-09-29 |
| CN107614004A (zh) | 2018-01-19 |
| CA2981705A1 (en) | 2016-09-29 |
| AU2019222918A1 (en) | 2019-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019222918B2 (en) | Antimicrobial peptides and methods of use thereof | |
| Boparai et al. | Mini review on antimicrobial peptides, sources, mechanism and recent applications | |
| De La Fuente-Núñez et al. | Synthetic antibiofilm peptides | |
| US12115209B2 (en) | ROMO1-derived antimicrobial peptides including lysine substitution and variants thereof | |
| EP2994154A1 (en) | Antimicrobial peptide | |
| KR101953828B1 (ko) | 왕귀뚜라미에서 유래한 항균 펩타이드 테레오그릴루신 1 및 그의 조성물 | |
| KR101740551B1 (ko) | 벼메뚜기에서 유래한 항균 펩타이드 옥시야신-2 및 그의 조성물 | |
| KR101953834B1 (ko) | 왕귀뚜라미에서 유래한 항균 펩타이드 테레오그릴루신 2 및 그의 조성물 | |
| US11266712B2 (en) | Antimicrobial peptides and methods of using the same | |
| CN117138024B (zh) | 一种万古霉素-抗菌肽偶合物及其应用 | |
| KR101889403B1 (ko) | 바퀴벌레에서 유래한 항균 펩타이드 페리플라네타신-4 및 그의 조성물 | |
| KR101889404B1 (ko) | 바퀴벌레에서 유래한 항균 펩타이드 페리플라네타신-5 및 그의 조성물 | |
| KR101851134B1 (ko) | 바퀴벌레에서 유래한 항균 펩타이드 페리플라네타신-6 및 그의 조성물 | |
| KR101820086B1 (ko) | 벼메뚜기에서 유래한 항균 펩타이드 옥시야신-4 및 그의 조성물 | |
| Umnyakova et al. | Peptides and antibiotic resistance | |
| EP3866826B1 (en) | Antimicrobial peptides and methods of using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: ADD INVENTOR WOODBURN, KATHRYN |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ JAYNES, JESSE; CLEMENS, L. EDWARD; LOPEZ, HENRY W.; MARTIN, GEORGE R. AND WOODBURN, KATHRYN |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |